Glycaemic control with add-on thiazolidinedione or a sodium-glucose co-transporter-2 inhibitor in patients with type 2 diabetes after the failure of an oral triple antidiabetic regimen: A 24-week, randomized controlled trial.
Jaehyun BaeJi Hye HuhMinyoung LeeEun Young LeeByung-Wan LeePublished in: Diabetes, obesity & metabolism (2020)
The current study shows that an SGLT2i or TZD could be a valid option as a fourth OAD for treatment of patients with T2D inadequately controlled with a triple combination of OADs.